ovarian cancer
Conditions
Interventions
Experimental Group:Paclitaxel: 175mg/m2 iv d1, q3w, 6-8 cycles Carboplatin AUC=5 iv d1, q3w, 6-8 cycles Apatinib: 425mg po, qd, q3w, 6-8 cycles
Control :PaclPaclitaxel: 175mg/m2 iv d1, q3w, 6-8 cycles Carboplatin AUC=5 iv d1, q3w, 6-8 cycles
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old female; 2. Pathologically diagnosed with III-IV stage epithelial ovarian cancer, fallopian tube cancer(FTC) or primary peritoneum cancer(PPC); 3. Have received cytoreductive surgery; 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 5. Life expectancy greater than or equal to 3 months; 6. Major organ function has to meet the following certeria: 1) For results of blood routine test: HB=90 g/L; ANC=1.5×10^9/L; PLT=80×10^9/L; 2) For results of blood biochemical test: ALT and AST=2.5 ULN, but =5 ULN if the transferanse elevation is due to liver metastase; TBIL<1.5?ULN; Serum creatinine =1.5?ULN; 7. Doctors believe that treatment can bring benefits to patients; 8. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. With high blood pressure and antihypertensive drug treatment can not control; 2. Patients with severe cardiovascular disease 3. Patients with other malignant tumors within 5 years (except for the treated skin basal cell carcinoma and cervical carcinoma in situ); 4. Patients with active bleeding or bleeding tendency; 5. Pregnant or lactating women; 6. The researchers think inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;Safety; | — |
Countries
China
Contacts
Public ContactShan Kang
Fourth Hospital of Hebei Medical University
Outcome results
None listed